Despite the results, Martin Holst Lange, Chief Scientific Officer and Executive Vice President of Research and Development at Novo Nordisk, said in the press release, We are proud to have conducted two well-controlled phase 3 trials in Alzheimers disease that meet the highest standards of research and rigorous methodology. Scientists like Sally Frautschy, a neuroscientist studying AD at the University of California, Los Angeles, agreed that the trial was well-designed to answer the question, and told DDN that Alzheimers involves clear deficits in insulin signaling, so GLP-1 receptor agonists were a logical target. However, Frautschy was not surprised by the results
Feb 28, 2026 Before you put that vial in the freezer, stop
Analyze Total Cost of Ownership: Factor in costs for cold shipping, import duties, and potential regulatory testing, not just unit price
However, a much higher dose of semaglutide is needed to achieve similar results (25mg to 50mg orally
Promotes eye health*
Does the Precision Peptide Genetic Test determine which GLP-1 I should take